ASCO and Ipi/Braf Combo Trial News

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

ASCO and Ipi/Braf Combo Trial News

This topic has 6 replies, 3 voices, and was last updated 13 years, 9 months ago by EmilyandMike.

Post

- June 2, 2011 at 6:01 pm
- Quote
EmilyandMike
Participant
A few years ago, I never thought I would follow an oncology conference with excitement. But here I am and I am sure you have seen a lot of news on melanoma due to the upcoming ASCO conference this weekend since melanoma drugs are a top focus at the conference. The results of the Ipi trials are what I am waiting to hear about, but here is a good overview of the "Drugs to Watch at ASCO". The last paragraph seems interesting – regarding the drug P28 for solid tumors: http://seekingalpha.com/article/272953-drugs-to-watch-at-asco-2011

AND

A few years ago, I never thought I would follow an oncology conference with excitement. But here I am and I am sure you have seen a lot of news on melanoma due to the upcoming ASCO conference this weekend since melanoma drugs are a top focus at the conference. The results of the Ipi trials are what I am waiting to hear about, but here is a good overview of the "Drugs to Watch at ASCO". The last paragraph seems interesting – regarding the drug P28 for solid tumors: http://seekingalpha.com/article/272953-drugs-to-watch-at-asco-2011

AND

This press release came out today announcing a Roche/BMS combo trial for the BRAF inhibitor and Ipi. Good news!

http://www.fiercebiotech.com/press-releases/roche-enters-collaboration-bristol-myers-squibb-study-combination-therapy-v

Viewing 3 reply threads

Replies

- - June 3, 2011 at 2:15 am
  - Quote
  deirgey
  Participant
  Very interesting. A brief recap of the melanoma info from the event would be very much appreciated if at all possible! 🙂
  
  Thanks,
  
  Deidre Grief (Father Stage IV)
- - June 3, 2011 at 2:15 am
  - Quote
  deirgey
  Participant
  Very interesting. A brief recap of the melanoma info from the event would be very much appreciated if at all possible! 🙂
  
  Thanks,
  
  Deidre Grief (Father Stage IV)
- - June 3, 2011 at 2:45 am
  - Quote
  slpinion
  Participant
  Thank you for posting both links…….much appreciated.
  
  Sharon in GA, stage III
  - June 3, 2011 at 3:11 am
    
    Quote
    EmilyandMike
    Participant
    
    Forgot to mention that the MRF is also hosting the wrap up of the ASCO news on the 13th. I am sure that will be a great webinar.
    
    I am praying for some great research results!
  - June 3, 2011 at 3:11 am
    
    Quote
    EmilyandMike
    Participant
    
    Forgot to mention that the MRF is also hosting the wrap up of the ASCO news on the 13th. I am sure that will be a great webinar.
    
    I am praying for some great research results!
- - June 3, 2011 at 2:45 am
  - Quote
  slpinion
  Participant
  Thank you for posting both links…….much appreciated.
  
  Sharon in GA, stage III

Viewing 3 reply threads

You must be logged in to reply to this topic.

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.